The study’s findings challenge prior expectations that T cells collected from subjects who have recently eaten versus those who have fasted would exhibit negligible differences. Instead, Greg Delgoffe, Ph.D., professor of immunology at the University of Pittsburgh and senior author of the study, emphasizes that the results were unexpected not only in magnitude but also in their persistence. The observed metabolic and functional benefits endured for days and could significantly impact how T cells respond upon encountering pathogens or malignant cells.

Mechanistically, the data suggest that circulating dietary lipids, transported in chylomicrons postprandially, serve as a critical nutrient source fueling enhanced T cell metabolism. These lipids enable increased protein synthesis within the T cells, a process essential for mounting effective immune responses. Importantly, the enhanced functional state was not driven by transcriptional changes but rather by post-transcriptional modifications and metabolic shifts that optimize the cells’ readiness for activation.

To establish translational relevance, the researchers conducted blood sampling on human volunteers before breakfast and again approximately six hours after eating. T cells isolated during the postprandial window displayed superior metabolic fitness and responsiveness to activating stimuli, suggesting that the timing of immune cell collection or activation may have profound implications for immunotherapeutic strategies. This insight opens a new paradigm, where the metabolic context of immune cells could be manipulated or leveraged to augment immunological outcomes.

Extending these observations, murine models confirmed that the post-meal metabolic advantage of T cells was robust and long-lasting. When T cells harvested after feeding were subsequently activated up to seven days later, they demonstrated enhanced effector function and durability. This durability highlights a previously unappreciated metabolic memory state that could influence immune surveillance and defense mechanisms in vivo.

The implications for cancer immunotherapy, particularly chimeric antigen receptor T cell (CAR-T) therapy, are transformative. CAR-T treatment efficacy depends on the quality and persistence of engineered T cells reinfused into patients. In preclinical tumor models, CAR-T cells derived from postprandial T cells showed superior tumor control and longer persistence relative to those generated from fasted donors. These findings suggest that metabolic priming through nutritional status could be a critical variable in optimizing CAR-T manufacturing and therapeutic effectiveness.

Despite these promising results, the study cautions against equating eating with direct treatment benefits for cancer or other diseases. Rather, it emphasizes that immune cell functionality is context-dependent and time-sensitive, factors that have been overlooked in both research and clinical practice. This temporal metabolic dimension could reshape protocols for immune profiling, cell collection, and immune-based interventions.

The collaborative effort integrated expertise spanning immunology, metabolism, and nutrition to dissect the complex biological interactions underpinning this phenomenon. By systematically interrogating T cell metabolic pathways, protein synthesis machinery, and lipid uptake, the team elucidated a clear causal pathway linking dietary fats to enhanced immune cell bioenergetics and function.

Further research is needed to explore how different types of meals, dietary compositions, and metabolic states modulate this effect and how it intersects with chronic diseases, infection susceptibility, and age-related immune decline. The identification of postprandial lipids as modulators of T cell performance also raises intriguing questions about the role of the gut-immune axis and metabolic signaling networks in orchestrating immune readiness.

Ultimately, these insights herald a new frontier in immunometabolism where food intake is not merely a backdrop for immune function but a dynamic modulator that can be harnessed for therapeutic gain. By aligning metabolic cues with immune activation windows, clinicians and researchers could refine immunotherapies and vaccination strategies to maximize efficacy and patient outcomes.

—
Subject of Research: Immunology, T cell metabolism and function, postprandial effects on immune response
Article Title: Postprandial lipid metabolism durably enhances T cell immunity
News Publication Date: 29-Apr-2026
Web References: https://www.nature.com/articles/s41586-026-10432-8, http://dx.doi.org/10.1038/s41586-026-10432-8
Image Credits: Greg M. Delgoffe, Ph.D.
Keywords: Immunology, T cell activation, Diets, Cancer, Immune response, CAR-T cell therapy, Postprandial metabolism, Lipid metabolism, Protein synthesis, Immunotherapy, Immunometabolism, Nutritional immunology

In a breakthrough study published in Protein & Cell, researchers delved deeply into the mechanistic underpinnings of post-RT metabolic flares, integrating rigorous analyses of both human tumor specimens and sophisticated murine cancer models. Their findings pivotally identify the upregulation of intracellular adhesion molecule-1 (ICAM-1) in tumor tissues as a critical instigator of these PET imaging flare-ups. RT robustly boosts ICAM-1 expression within the tumor microenvironment, a process intricately linked with enhanced infiltration and clustering of tumor-resident T cells, effectively reprogramming their metabolic and functional states.

Genetic ablation experiments revealed that loss of ICAM-1 severely diminished the magnitude of RT-induced ^18F-FDG flares. This attenuation was traceable predominantly to a reduction in T cell glucose uptake and intratumoral accumulation, rather than fluctuations in myeloid cell activity. These data decisively shift the paradigm, elevating T cells—rather than mere inflammatory cells—as primary drivers of the metabolic signals detected by ^18F-FDG PET post-radiotherapy.

At the molecular signaling level, RT-induced ICAM-1 was shown to engage lymphocyte function-associated antigen-1 (LFA-1), one of its principal binding partners on T cells. This interaction orchestrates clustering and retention of T cells within tumors. Crucially, this ICAM-1/LFA-1 mediated adhesion event activates a downstream signaling cascade governed by the PI3K–AKT–mTOR axis, well known for its pivotal role in cellular metabolism and immune cell effector function.

Activation of the PI3K–AKT–mTOR pathway triggers profound metabolic rewiring in T cells, characterized by increased glycolysis and enhanced tricarboxylic acid (TCA) cycle flux. This metabolic reprogramming equips tumor-infiltrating T cells with the bioenergetic and biosynthetic capacity to sustain robust effector functions in the hostile tumor microenvironment. The elevated glucose metabolism of these T cells, visualized by heightened ^18F-FDG uptake, explains the observed PET flares post-radiotherapy and links metabolic imaging signals directly to adaptive immune dynamics.

This mechanistic insight fundamentally enriches the clinical interpretation of post-RT PET scans. Traditionally, increased ^18F-FDG signals have been confounded as either tumor progression or inflammatory pseudoprogression, complicating therapeutic decision-making. The identification of ICAM-1 as a marker of T cell metabolic engagement offers a novel biomarker to distinguish these distinct biological phenomena, fostering more precise and individualized treatment monitoring.

Importantly, these discoveries open promising avenues to harness metabolic imaging as a proxy for intratumoral immune activity, offering clinicians a window into antitumor immune responses elicited by RT. This could be pivotal for optimizing RT-based combination therapies, particularly those integrating immune checkpoint inhibitors or adoptive T cell transfer strategies, where timely assessment of immune activation dictates therapeutic success.

From a therapeutic development perspective, targeting the ICAM-1/LFA-1 axis or its downstream PI3K–AKT–mTOR signaling cascade may modulate T cell infiltration and function in tumors. Such interventions could synergize with RT to amplify antitumor immunity or circumvent resistance mechanisms. Moreover, metabolic modulation of T cells guided by this pathway provides a strategic focal point for designing novel immunometabolic therapies.

This study exemplifies an integrative systems biology approach, fusing tumor biology, immunology, metabolic analysis, and advanced imaging, underscoring the complex crosstalk between tumor cells and immune components after radiotherapy. It heralds a new era in which metabolic imaging transcends mere structural assessment, evolving into a dynamic biomarker of immune competence within the tumor microenvironment.

In summary, the upregulation of ICAM-1 following radiotherapy acts as a molecular rheostat coordinating T cell clustering via ICAM-1–LFA-1 interactions. This interaction potentiates PI3K–AKT–mTOR-driven metabolic reprogramming of T cells, boosting their glycolytic activity and tumor infiltration. The resultant surge in ^18F-FDG uptake visualized on PET scans—the metabolic flare—is thus an emblem of active antitumor immune engagement, redefining how clinicians should interpret post-RT metabolic imaging.

The implications of these findings extend beyond diagnostic imaging, inviting a reconceptualization of radiotherapy’s immunomodulatory effects and instigating the design of more rational, metabolism-aware combination therapies. Ultimately, this research bridges critical gaps in understanding the interplay between radiotherapy, immune dynamics, and tumor metabolism, spotlighting ICAM-1 as a linchpin in orchestrating effective antitumor T cell responses.

Subject of Research: Not applicable
Article Title: ICAM-1 promotes T cell glycolytic reprogramming and tumor infiltration to drive 18F-FDG PET flares following radiotherapy
News Publication Date: 19-Dec-2025
Web References: http://dx.doi.org/10.1093/procel/pwaf111
Image Credits: HIGHER EDUCATION PRESS
Keywords: Cell biology